WO2022079498A1 - Composition for the prevention of infection by sars-cov-2 - Google Patents
Composition for the prevention of infection by sars-cov-2 Download PDFInfo
- Publication number
- WO2022079498A1 WO2022079498A1 PCT/IB2021/052900 IB2021052900W WO2022079498A1 WO 2022079498 A1 WO2022079498 A1 WO 2022079498A1 IB 2021052900 W IB2021052900 W IB 2021052900W WO 2022079498 A1 WO2022079498 A1 WO 2022079498A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- composition
- hydroxytyrosol
- administration
- mouthwash
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 230000002265 prevention Effects 0.000 title claims description 17
- 208000015181 infectious disease Diseases 0.000 title description 13
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 claims abstract description 102
- 235000003248 hydroxytyrosol Nutrition 0.000 claims abstract description 49
- 229940095066 hydroxytyrosol Drugs 0.000 claims abstract description 49
- 239000007921 spray Substances 0.000 claims abstract description 44
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims abstract description 38
- 239000002324 mouth wash Substances 0.000 claims abstract description 35
- 229940051866 mouthwash Drugs 0.000 claims abstract description 35
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims abstract description 32
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims abstract description 31
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 20
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims abstract description 13
- 206010006326 Breath odour Diseases 0.000 claims abstract description 11
- 208000032139 Halitosis Diseases 0.000 claims abstract description 11
- 230000002035 prolonged effect Effects 0.000 claims abstract description 7
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 239000002537 cosmetic Substances 0.000 claims abstract description 5
- 229940126601 medicinal product Drugs 0.000 claims abstract description 4
- 150000002148 esters Chemical class 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 230000009467 reduction Effects 0.000 claims description 9
- 210000004877 mucosa Anatomy 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 210000002850 nasal mucosa Anatomy 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 241001678559 COVID-19 virus Species 0.000 description 24
- 150000002632 lipids Chemical class 0.000 description 20
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 17
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 17
- 230000012202 endocytosis Effects 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 210000000170 cell membrane Anatomy 0.000 description 11
- 239000007621 bhi medium Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 101710198474 Spike protein Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 229940096437 Protein S Drugs 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 6
- 241000315672 SARS coronavirus Species 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 230000007123 defense Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 235000021436 nutraceutical agent Nutrition 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000002417 nutraceutical Substances 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000711573 Coronaviridae Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241001440871 Neisseria sp. Species 0.000 description 4
- 241000194022 Streptococcus sp. Species 0.000 description 4
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 150000003408 sphingolipids Chemical class 0.000 description 3
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 2
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 235000011576 oleuropein Nutrition 0.000 description 2
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QWBFVHOFYPYQHT-UHFFFAOYSA-N 1-sulfanylundecane-1-sulfonic acid Chemical group CCCCCCCCCCC(S)S(O)(=O)=O QWBFVHOFYPYQHT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 108020000949 Fungal DNA Proteins 0.000 description 1
- 208000034619 Gingival inflammation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 235000001412 Mediterranean diet Nutrition 0.000 description 1
- 241000008906 Murine coronavirus Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000032370 Secondary transmission Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 241001147693 Staphylococcus sp. Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000006781 columbia blood agar Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the invention concerns a composition to strengthen the defenses in the context of the COVID- 19 pandemic caused by the severe acute respiratory syndrome coronavirus 2, abbreviated as SARS-CoV-2, and to help to effectively prevent an infection from SARS-CoV-2.
- the composition can be administered orally, preferably in the form of a spray, but alternatively it can be administered nasally, in this regard the composition can be applied, for example, through a food supplement, a medical device, a cosmetic mouthwash, a traditional herbal medicinal product (botanical), a food for special medical purposes, and this preferably in the form of a spray or in liquid format.
- the SARS-CoV-2 virus resides in the mucous membranes:
- the SARS-CoV-2 virus is able to attack, at first instance, the cells of the respiratory mucous membranes, where it may reside for two days before spreading to the lower respiratory tract, as evidenced for SARS-CoV virus in macaques (SARS-CoV virus is very similar to SARS-CoV-2 virus for the cell tropism) [1], Human-to-human transmission of the virus occurs through coughing, sneezing, inhalation of droplets and direct contact with the mouth, nose and eyes with contaminated hands [2], The infection has an average incubation period of 6.4 days and a basic reproduction of 2.24 - 3.58 [3].
- All respiratory viruses with envelope such as SARS-CoV-2
- SARS-CoV-2 bind to specific cell membrane receptors that facilitate their entry into the cell itself.
- Cellular infection occurs through two phases i) binding of the virus to the cell through surface viral proteins attaching to cell membrane receptors and ii) membrane fusion induced by conformational changes in the fusion proteins [4]
- the SARS-CoV-2 virus uses the Spike (S) protein present in the envelope to bind the cellular ACE2 receptor located in the lipid rafts.
- ACE2 cuts the Spike protein proteolytically, this induces a series of mechanisms that lead to viral endocytosis.
- the ACE2 receptor binds to the Spike protein only when it is localized in lipid rafts [5],
- Lipid rafts are membrane subdomains characterized by a high content of sphingolipids, cholesterol and proteins [6]. Numerous studies have revealed that lipid rafts are important during coronavirus viral infection. Studies have shown that drug-mediated elimination of cholesterol inhibits the entry of human coronaviruses [7, 8] into host cells. Furthermore, lipid rafts have been reported to be crucial for SARS-CoV entry into Vero E6 cells [9], Lipid rafts can be destroyed by cell cholesterol depletion via methyl - ⁇ -cyclodextrin ( M ⁇ CD) [10], In fact, it has been found that the integrity of the lipid raft is necessary for the productive infection of SARS-CoV (virus very similar to SAR.S-CoV-2). Treatment with M ⁇ CD relocates the ACE2 receptor outside the lipid raft and this treatment is able to inhibit SARS-CoV infectivity by 90% [9],
- ⁇ -cyclodextrins are able to bind cholesterol, whereas ⁇ -cyclodextrins, with a smaller internal cavity, cannot bind cholesterol, but are able to bind membrane phospholipids and sphingolipids.
- cyclodextrins can influence the composition of the cell membrane as evidenced by a study published in 2007; in this case, it was found that ⁇ -cyclodextrin could reduce the cholesterol content of the plasma membrane [11], Methyl - ⁇ - cyclodextrin reduces the amount of cholesterol in cell membranes and can inhibit the attack of coronaviruses on host cells [10, 12], Exposure to M ⁇ CD can also lead to the redistribution of cholesterol between lipid rafts and non-raft regions [11], In vitro cellular models have shown that cholesterol depletion by M ⁇ CD halves the number of ACE2 receptor bonds with viral S- glycoproteins [5], Some studies have also shown that treatment with M ⁇ CD slightly and dose- dependently reduces the expression of ACE2 in the cell membrane, reducing the infectivity of coronaviruses [13],
- the scope of the invention is to effectively enhancing the defenses for the prevention of SARS CoV-2 infection.
- a further scope of the invention is to find an effective composition for the aforementioned prevention that can be applied orally by spray.
- Another scope of the invention is to identify such a composition consisting of nutraceutical components.
- composition which includes (as active ingredients):
- the composition is a composition for an application as a food supplement or with a medical device.
- it is a composition for application as medical device, cosmetic mouthwash, traditional medicine of vegetable origin (botanical), or food for special medical purposes.
- the composition preferably further comprises hy droxypropyl methyl cel lul ose .
- hydroxytyrosol can also be called 4-(2-hydroxy ethyl)- 1,2- di hydroxybenzene (n. CAS 10597-60-1). Both ⁇ -cyclodextrin and hydroxytyrosol are already approved as novel food by European legislation.
- the hypothesis of the inventors is the possibility to take advantage of the lipid rafts disruption by modifying their composition and influencing the subsequent endocytosis of SARS-CoV-2 or other viruses that share the same mechanism of lipid-raft mediated endocytosis, being this protection non specific.
- ⁇ -cyclodextrins can act in this sense: it has been proven that ⁇ -cyclodextrin is able to replace sphingolipids and phospholipids in the outer layer of the plasma membrane with exogenous lipids in mammalian cells, thus acting in a bidirectional way [14], Furthermore, thanks to their structure, ⁇ -cyclodextrins preferably bind saturated fatty acids, which, together with cholesterol, make up lipid rafts. Therefore, it is plausible that ⁇ -cyclodextrins can modify the composition of lipid rafts, destabilizing them.
- ⁇ -cyclodextrin has already been used with a different mechanism of action in which they reduced the concentration of serum phospholipids in equilibrium with the membrane phospholipids. This reduced serum concentration causes a malfunction of the cellular pathways on the membrane exploited by the virus for endocytosis in the cell [15], In another work by Wittkowski it was highlighted how the ⁇ -cyclodextrins, being smaller, are not able to deplete cholesterol, but phospholipids.
- hydroxypropyl- ⁇ -cyclodextrin is twice as effective as hydroxypropyl - ⁇ -cyclodextrin against the migration of human breast cancer cells involving an endocytosis/exocytosis mechanism [16]
- ⁇ -cyclodextrin was modified with mercaptoundecane sulfonic acid, to mimic heparan sulfate and block heparan sulfate-dependent viruses such as HSV-2 [17].
- Hydroxytyrosol is a phenolic compound with antioxidant properties obtained from olive extracts.
- hydroxytyrosol exhibits antiinflammatory and anti-viral activity. In vivo a bacteriostatic activity has been noted, too. Hydroxytyrosol has antiviral effects on the influenza virus, in fact hydroxytyrosol appears to cause morphological changes in the H9N2 influenza virus pretreated with hydroxytyrosol, without affecting neuraminidase or haemagglutinin activity [18]. Hydroxytyrosol has also been shown to be an inhibitor of fusion (lipid raft mediated endocytosis [19]) and integration of HIV- 1.
- Hydroxytyrosol binds to the viral protein gp41, interfering with the fusion of the viral membrane with the cellular membrane. Hydroxytyrosol shows a dose-dependent inhibition, without detectable cytotoxicity [20], In addition, hydroxytyrosol also binds to HIV-1 integrase.
- Hydroxytyrosol binds to region II of the integrase active site, inhibiting its activity in a dosedependent manner [21], Hydroxytyrosol is also able to induce an anti-inflammatory effect, decreasing the levels of pro-inflammatory cytokines such as IL-6 and TNF-a in animal models [22], Finally, in mouse models it was found that hydroxytyrosol is able to lower serum lipids in rats fed a diet rich in cholesterol [23], thus being able to act indirectly on the composition of the plasma membrane. Hydroxytyrosol interacts directly with the plasma membrane and localizes at the level of the hydrophilic heads.
- hydroxytyrosol can have bacteriostatic effects [25, 26] and this property, in a preferred embodiment of the invention, could be exploited to counteract, contemporarily with the prevention according to the invention, halitosis due to prolonged use of facial masks. Bacteriostatic effects have been shown in strains of Candida sp., Staphylococcus aureus. Streptococcus spp.
- hydroxytyrosol in combination with ⁇ -cyclodextrins, has promising activities in the prevention of SARS-CoV-2 infection wherein the cyclodextrin serves as a vehicle for hydroxytyrosol and both compete in the occupation of the attack sites on the cell membranes of the host cells.
- a preferred formulation of the invention therefore provides for the application of the composition in the prevention of SARS-CoV-2 infection. Prevention takes place in a specific and effective way. At the same time, the combination can obviously have other virucidal or therapeutic effects, such as those already known for hydroxytyrosol. In particular, the above mentioned bacteriostatic effects can be exploited.
- a further preferred embodiment of the invention involves the simultaneous application of the composition in combating halitosis due to prolonged mask use. Hypothetical is the application of the composition also only for contrasting halitosis in subjects who wear a mask for prolonged times.
- the components of the composition are present in effective quantities, that is, effective in the prevention of SARS-CoV-2 infection, as shown by the observational and interventional studies conducted.
- the composition is present in the form of an aqueous solution in which hydroxytyrosol is present in a concentration of about 3.80-11.40% (m/m) and ⁇ -cyclodextrin is present in a concentration of about 0.20-0.60% (m/m).
- the specific solution mentioned above has a density of 1.1 g/ml. Also lower concentrations of hydroxytyrosol (from 1.00 to 11.40 % (m/m)) in the combination have been shown to be effective in contrasting halitosis. In this case, the density varies from 1.0 to 1.1 g/ml.
- Other solvents or excipients are conceivable, as it is conceivable to add further components usual in the sector, such as flavorings.
- composition according to the invention can have oral application in the form of a spray.
- the application can be nasally.
- Nasal or oral applications as a spray or also in liquid form are feasible, in particular as a mouthwash, which is particularly suitable for combating halitosis.
- oral or nasal applications by spray or in liquid formulation are conceivable, for example as a food supplement, medical device, cosmetic mouthwash, traditional medicinal product of plant origin (botanical), food for special medicinal purposes.
- oral application or oral administration by means of a spray or as a mouthwash involves applying the composition to the oropharyngeal mucosa.
- the oral application via spray, or alternatively as a mouthwash, or the nasal administration foresees an application of the composition on the nasal or oropharyngeal mucosa.
- composition as described above presents an opportunity to strengthen the defenses through the non-specific but effective reduction against SARS-CoV-2 of the process of lipid raft mediated endocytosis and consequently of prevention [2], also taking advantage of the fact that the virus probably stops and replicates exponentially for two days on the mucous membranes before its diffusion in the lower airways [31], thus interfering with endocytosis, the biological cycle of the virus is limited, made by exocytosis, endocytosis and multiplication. Furthermore, as already explained above, in its formulation as a mouthwash, the composition has a bacteriostatic effect that reduces the growth in the oral cavity of bacteria responsible for halitosis from prolonged use of the mask [27],
- application on the oropharyngeal mucosa is an application as a spray that performs its action topically.
- the application on the oropharyngeal mucosa is an application as a mouthwash that performs its action topically.
- the application is done on the nasal mucosa, in particular as a spray.
- the application involves repeated applications, even without time limitations, preferably twice a day, preferably after careful oral hygiene, each for a total of 0.5 ml of the aqueous solution as specified above.
- each 0.5 ml dose is applied with four sprays from a spray dispensing device, each spray delivering approximately 0.125 mL of solution.
- the inventors therefore propose for the first time the use of the combination of hydroxytyrosol and ⁇ -cyclodextrin to strengthen non-specific defenses through the reduction of the endocytosis process and consequent reduction of the risk of SARS-CoV-2 infection based on the principle that ⁇ -cyclodextrin inhibits lipid raft mediated endocytosis and hydroxytyrosol has a destabilizing action on the plasma membrane.
- Bioinformatics studies show how both hydroxytyrosol and ⁇ -cyclodextrin interact with the proteins necessary for viral endocytosis.
- a second aspect of the invention concerns a dispensing device which comprises (i) a container containing the composition according to the invention;
- the spray head is advantageously adapted to deliver doses after activation, the multiple of which, preferably four, corresponds to 0.5 ml of said aqueous solution.
- the multiple corresponds to 1 mL of said aqueous solution. It thus allows the application of correct amounts of the active ingredients.
- eight spray doses are foreseen which correspond to 0.5 or 1 mL of solution.
- the device according to the invention can also comprise the composition according to the invention in the form of a mouthwash.
- a further aspect of the invention concerns a method for the treatment or the prevention of SARS-CoV-2 infection which involves the application of the composition according to the invention in particular on the oropharyngeal mucosa, or in alternative on the nasal mucosa. It is therefore the use of the composition according to the invention for the prevention of SARS- CoV -2 infection. It is therefore the use of the composition according to the invention for the prevention of SARS- CoV-2 infection.
- the application takes place in concentrations (dosages) and according to the administration plan illustrated above.
- a final aspect of the invention relates to a process for the production of a composition referred to in which ⁇ -cyclodextrin and hydroxytyrosol and/or their nutraceutical and/or pharmaceutically acceptable derivatives are mixed.
- the two components are dissolved in water, in particular in the amounts indicated above.
- composition according to the invention is effective in preventing SARS-CoV-2 infection, has no side effects, shows no cytotoxic effects and contains nutraceutical components.
- Fig. 1 shows the results of a cytotoxicity test of a spray containing ⁇ -cyclodextrin and hydroxytyrosol on the human cell line Caco-2.
- Fig. 2 shows the results of a cytotoxicity test of a spray containing ⁇ -cyclodextrin and hydroxytyrosol on the human cell line HepG2.
- Fig. 3 shows the potential binding sites of hydroxytyrosol with the proteins ACE2, TMPRSS2 and Spike.
- Fig. 4 shows the potential binding sites of ⁇ -ciclodestrina with the proteins ACE2, TMPRSS2 and Spike.
- Fig. 5 shows growth inhibition, ranging from 20 to 80%, in cultures of Candida albicans (A), Staphylococcus aureus (B) and a mix of bacteria (Streptococcus sp., Staphylicoccus sp. and Neisseria sp.) from throat swab (C), grown in standard culture medium (below) and in standard culture medium with the addition of mouthwash according to the invention (above).
- Candida albicans A
- Staphylococcus aureus B
- a mix of bacteria Streptococcus sp., Staphylicoccus sp. and Neisseria sp.
- Fig. 6 shows the reduction of DNA amplification by PCR of bacterial (A) and fungal (B) DNA after using the mouthwash (samples 7, 8 and 9) in individuals who have worn the mask continuously for 8 hours, while it is highlighted a greater presence of bacteria and fungi after using the mask for 8 hours without using mouthwash.
- an aqueous solution of ⁇ -cyclodextrin and hydroxytyrosol is produced in which hydroxytyrosol is present in a concentration of 3.80 - 11,40 % (m/m), whereas ⁇ -cyclodextrin has a concentration of 0.20-0.60% (m/m).
- the solution is transferred into a spray dispensing device and is thus usable as a spray.
- the composition has antioxidant properties as showed in a ORAC assay (Oxygen Radical Absorbance Capacity), that demonstrate an antioxidant capacity of 1,247.43 ⁇ 4.05 pmol TE/ml (micromoles of Trolox® (TE) per milliliter of the sample).
- ORAC assay Oxygen Radical Absorbance Capacity
- TE Trolox®
- the antioxidant properties of the human milk of mothers fed with a Mediterranean diet has an antioxidant power of 584.16 ⁇ 29.51 pmol TE/ml.
- the spray was tested on 87 volunteers negative for COVID-19 and with different clinical characteristics (table 1) in a observational study without controls. None of these individuals after using the spray for a week has shown any side effects or interactions with drugs taken for other diseases. The volunteers took two doses per day, each dose corresponds to four spray doses for a total of 0.5 ml of solution (3.80 % (m/m) of hydroxytyrosol and 0.20% (m/m) of ⁇ -cyclodextrin.
- Continuous exposure means health workers in continuous contact with COVID-19 patients or cohabiting with sick subjects. By occasional, we mean any contact with a casual and not protracted positive subject as it can be in public transport or at a restaurant.
- Table 1 The results shown in Table 1 are a first clue to the effectiveness of the spray in the prevention of COVID-19.
- the percentage of subjects who can acquire the infection after contact at risk is not certain, but it is estimated that it can range from a minimum of 30% of contacts up to 80%. Wang et al.
- the invention achieved the aim of proposing a composition with nutraceutical active ingredients that are effective in preventing SARS-CoV-2 infection and that do not have side effects or signs of cytotoxicity.
- the proposed oral administration allows in particular the local (topical) action of the two components in the oropharyngeal mucosa, made possible by the particular combination of ⁇ -cyclodextrin and hydroxytyrosol.
- Continuous exposure means health workers in continuous contact with COVID-19 patients or cohabiting with sick subjects. By occasional, we mean any contact with a casual and not protracted positive subject as it can be in public transport or at a restaurant.
- Fig. 3 illustrates the potential binding sites of hydroxytyrosol with the proteins ACE2, TMPRSS2 and Spike
- fig. 4 illustrates the potential binding sites of ⁇ -cyclodextrin with ACE2, TMPRSS2 and Spike proteins.
- ⁇ -cyclodextrin can bind to both the viral spike protein and the host receptor protein ACE2 with a significantly higher binding affinity than hydroxytyrosol for the same proteins.
- the binding energies of ⁇ - cyclodextrin and hydroxytyrosol to ACE2 were 7.91 kcal/mol and 6.10 kcal/mol, respectively, while the corresponding binding energies to the spike protein were 6.40 kcal/mol and 6.41 kcal/mol, respectively.
- both compounds could inhibit the two targets by virtue of their significant binding affinities. These compounds can also form physical bonds with each other, and the resulting complex is predicted to bind efficiently to both proteins. Compared to its components, the binding energy of the complex is significantly higher for the ACE2 receptor and similar to the separate compounds for the spike protein [36], Finally, in vitro experiments were performed on animal cell lines, VeroE6. These experiments showed that at 0.8 pM a solution containing ⁇ -cyclodextrin and hydroxytyrosol is not cytotoxic and is able to inhibit viral replication (Table 6) [30],
- microorganisms The possible inhibition of the growth of microorganisms by a mouthwash containing the composition according to the invention was evaluated: hydroxytyrosol and ⁇ -cyclodextrin.
- the following microorganisms were isolated from throat swabs collected by sterile swabs and cultured:
- Candida albicans isolated from a lingual swab
- the microorganisms were inoculated into a standard liquid medium called Brain Heart Infusion (BHI) agar (Liofilchem).
- BHI Brain Heart Infusion
- Liofilchem Liofilchem
- FIG. 5 illustrates the inhibition of the growth that oscillates between 20 and 80 %, in the cultures of Candida albicans (A), Staphylococcus aureus (B) and a mix of bacteria (Streptococcus sp., Staphylicoccus sp. and Neisseria sp.) from throat swap (C), cultivated in standard culture medium (below) and in standard culture medium withy adding a mouthwash according to the invention (above).
- A Candida albicans
- B Staphylococcus aureus
- C a mix of bacteria
- DNA was extracted from saliva in three volunteers: without using the mask, after using the mask for 8 hours, after they had used the mask for 8 hours and then used the mouthwash. Then the extracted DNA was amplified with universal primers (for example Universal 16S rRNA bacterial primers 27F and Universal
- Panfungal ITS for the amplification of bacterial and fungal DNA as described in the references [37,38], to evaluate possible differences in microbial growth with or without the use of the facial mask and with or without the use of the mouthwash. It has been shown that there is an increase in bacterial and fungal growth when wearing the mask for 8 hours, while when the volunteers wore the mask for 8 hours and then used the hydroxytyrosol and ⁇ -cyclodextrin- based mouthwash, a reduction in the presence of bacteria and fungi was found, even compared to those who did not use the mask for 8 hours (figure 6) [27],
- Figure 6 show s ladders of DNA, wherein A (ladder 1 kb) refers to the primer Universal 16S rRNA bacterial primers 27F with a fragment length of 1440 bp and B (ladder 100 bp) to the primer Universal Panfungal ITS with a fragment length of 500 bp. From the left to the right, results without mask, with a use of the mask for 8 hours and with a use of the mask together with an application of the mouthwash according to the invention can be noted.
- A ladder 1 kb
- B ladder 100 bp
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition that comprises α-cyclodextrin and hydroxytyrosol and/or their nutraceutically acceptable derivatives, such as salts or esters, in particular for application as a food supplement or medical device, in alternative as a cosmetic mouthwash or traditional medicinal product of plant origin (botanical) or food for special medical purposes. The composition is effective in preventing SARS-CoV-2 infection. The composition is suitable for an application as a spray or mouthwash. A related dispensing device is also described. The composition is also effective in contrasting halitosis in subjects that wear a mask for a prolonged period.
Description
COMPOSITION FOR THE PREVENTION OF INFECTION BY SARS-CoV-2
TECHNICAL FIELD
The invention concerns a composition to strengthen the defenses in the context of the COVID- 19 pandemic caused by the severe acute respiratory syndrome coronavirus 2, abbreviated as SARS-CoV-2, and to help to effectively prevent an infection from SARS-CoV-2. The composition can be administered orally, preferably in the form of a spray, but alternatively it can be administered nasally, in this regard the composition can be applied, for example, through a food supplement, a medical device, a cosmetic mouthwash, a traditional herbal medicinal product (botanical), a food for special medical purposes, and this preferably in the form of a spray or in liquid format.
STATE OF THE ART
The SARS-CoV-2 virus resides in the mucous membranes: The SARS-CoV-2 virus is able to attack, at first instance, the cells of the respiratory mucous membranes, where it may reside for two days before spreading to the lower respiratory tract, as evidenced for SARS-CoV virus in macaques (SARS-CoV virus is very similar to SARS-CoV-2 virus for the cell tropism) [1], Human-to-human transmission of the virus occurs through coughing, sneezing, inhalation of droplets and direct contact with the mouth, nose and eyes with contaminated hands [2], The infection has an average incubation period of 6.4 days and a basic reproduction of 2.24 - 3.58 [3].
All respiratory viruses with envelope, such as SARS-CoV-2, bind to specific cell membrane receptors that facilitate their entry into the cell itself. Cellular infection occurs through two phases i) binding of the virus to the cell through surface viral proteins attaching to cell
membrane receptors and ii) membrane fusion induced by conformational changes in the fusion proteins [4], Specifically, the SARS-CoV-2 virus uses the Spike (S) protein present in the envelope to bind the cellular ACE2 receptor located in the lipid rafts. ACE2 cuts the Spike protein proteolytically, this induces a series of mechanisms that lead to viral endocytosis. The ACE2 receptor binds to the Spike protein only when it is localized in lipid rafts [5],
Lipid rafts are membrane subdomains characterized by a high content of sphingolipids, cholesterol and proteins [6], Numerous studies have revealed that lipid rafts are important during coronavirus viral infection. Studies have shown that drug-mediated elimination of cholesterol inhibits the entry of human coronaviruses [7, 8] into host cells. Furthermore, lipid rafts have been reported to be crucial for SARS-CoV entry into Vero E6 cells [9], Lipid rafts can be destroyed by cell cholesterol depletion via methyl -β-cyclodextrin ( MβCD) [10], In fact, it has been found that the integrity of the lipid raft is necessary for the productive infection of SARS-CoV (virus very similar to SAR.S-CoV-2). Treatment with MβCD relocates the ACE2 receptor outside the lipid raft and this treatment is able to inhibit SARS-CoV infectivity by 90% [9],
The β-cyclodextrins are able to bind cholesterol, whereas α-cyclodextrins, with a smaller internal cavity, cannot bind cholesterol, but are able to bind membrane phospholipids and sphingolipids. In particular, it has been shown that cyclodextrins can influence the composition of the cell membrane as evidenced by a study published in 2007; in this case, it was found that β-cyclodextrin could reduce the cholesterol content of the plasma membrane [11], Methyl - β- cyclodextrin reduces the amount of cholesterol in cell membranes and can inhibit the attack of coronaviruses on host cells [10, 12], Exposure to MβCD can also lead to the redistribution of cholesterol between lipid rafts and non-raft regions [11], In vitro cellular models have shown that cholesterol depletion by MβCD halves the number of ACE2 receptor bonds with viral S- glycoproteins [5], Some studies have also shown that treatment with MβCD slightly and dose- dependently reduces the expression of ACE2 in the cell membrane, reducing the infectivity of coronaviruses [13],
Research aimed at combating the SARS-CoV-2 virus is currently concentrated in the pharmaceutical fields, while efforts in prevention are often aimed at improving the body's defenses. Besides vaccination, fully satisfactory solutions have not been identified so far.
DISCLOSURE OF THE INVENTION
The scope of the invention is to effectively enhancing the defenses for the prevention of SARS CoV-2 infection. A further scope of the invention is to find an effective composition for the aforementioned prevention that can be applied orally by spray. Another scope of the invention is to identify such a composition consisting of nutraceutical components.
In a first aspect of the invention, the scope is achieved by a composition which includes (as active ingredients):
(a) α-cyclodextrin,
(b) hydroxytyrosol and/or their derivatives, such as nutraceutical and/or pharmaceutically acceptable salts or esters In particular, the composition is a composition for an application as a food supplement or with a medical device. In alternative embodiments, it is a composition for application as medical device, cosmetic mouthwash, traditional medicine of vegetable origin (botanical), or food for special medical purposes. In its application as medical device, the composition preferably further comprises hy droxypropyl methyl cel lul ose .
According to IUPAC, hydroxytyrosol can also be called 4-(2-hydroxy ethyl)- 1,2- di hydroxybenzene (n. CAS 10597-60-1). Both α-cyclodextrin and hydroxytyrosol are already approved as novel food by European legislation. The hypothesis of the inventors is the possibility to take advantage of the lipid rafts disruption by modifying their composition and influencing the subsequent endocytosis of SARS-CoV-2 or other viruses that share the same mechanism of lipid-raft mediated endocytosis, being this protection non specific.
Results of a recent study support the hypothesis that α-cyclodextrins can act in this sense: it has been proven that α-cyclodextrin is able to replace sphingolipids and phospholipids in the outer layer of the plasma membrane with exogenous lipids in mammalian cells, thus acting in a bidirectional way [14], Furthermore, thanks to their structure, α-cyclodextrins preferably bind saturated fatty acids, which, together with cholesterol, make up lipid rafts. Therefore, it is plausible that α-cyclodextrins can modify the composition of lipid rafts, destabilizing them. Furthermore, α-cyclodextrin has already been used with a different mechanism of action in which they reduced the concentration of serum phospholipids in equilibrium with the
membrane phospholipids. This reduced serum concentration causes a malfunction of the cellular pathways on the membrane exploited by the virus for endocytosis in the cell [15], In another work by Wittkowski it was highlighted how the α-cyclodextrins, being smaller, are not able to deplete cholesterol, but phospholipids. For example, hydroxypropyl-α-cyclodextrin is twice as effective as hydroxypropyl - β-cyclodextrin against the migration of human breast cancer cells involving an endocytosis/exocytosis mechanism [16], In addition, the effects of α- cyclodextrin as a virucidal molecule have been described. In this case, α-cyclodextrin was modified with mercaptoundecane sulfonic acid, to mimic heparan sulfate and block heparan sulfate-dependent viruses such as HSV-2 [17]. Hydroxytyrosol, on the other hand, is a phenolic compound with antioxidant properties obtained from olive extracts. It is authorized as a nutraceutical compound and as a food supplement under both European and US legislation. In vivo, hydroxytyrosol exhibits antiinflammatory and anti-viral activity. In vivo a bacteriostatic activity has been noted, too. Hydroxytyrosol has antiviral effects on the influenza virus, in fact hydroxytyrosol appears to cause morphological changes in the H9N2 influenza virus pretreated with hydroxytyrosol, without affecting neuraminidase or haemagglutinin activity [18]. Hydroxytyrosol has also been shown to be an inhibitor of fusion (lipid raft mediated endocytosis [19]) and integration of HIV- 1. Hydroxytyrosol binds to the viral protein gp41, interfering with the fusion of the viral membrane with the cellular membrane. Hydroxytyrosol shows a dose-dependent inhibition, without detectable cytotoxicity [20], In addition, hydroxytyrosol also binds to HIV-1 integrase.
Hydroxytyrosol binds to region II of the integrase active site, inhibiting its activity in a dosedependent manner [21], Hydroxytyrosol is also able to induce an anti-inflammatory effect, decreasing the levels of pro-inflammatory cytokines such as IL-6 and TNF-a in animal models [22], Finally, in mouse models it was found that hydroxytyrosol is able to lower serum lipids in rats fed a diet rich in cholesterol [23], thus being able to act indirectly on the composition of the plasma membrane. Hydroxytyrosol interacts directly with the plasma membrane and localizes at the level of the hydrophilic heads. This could modify the physico-chemical properties of the membrane important for the process of lipid raft mediated endocytosis [24], Therefore, for hydroxytyrosol there are generally anti-viral activities, but to the knowledge of the inventors, so far it has never been used in the SARS-CoV-2 context. In addition, hydroxytyrosol can have bacteriostatic effects [25, 26] and this property, in a preferred
embodiment of the invention, could be exploited to counteract, contemporarily with the prevention according to the invention, halitosis due to prolonged use of facial masks. Bacteriostatic effects have been shown in strains of Candida sp., Staphylococcus aureus. Streptococcus spp. with a growth reduction of 40% [27]. The inventors have discovered, through bioinformatics approach that, hydroxytyrosol, in combination with α-cyclodextrins, has promising activities in the prevention of SARS-CoV-2 infection wherein the cyclodextrin serves as a vehicle for hydroxytyrosol and both compete in the occupation of the attack sites on the cell membranes of the host cells. Furthermore, using the bioinformatics tool D3DOCKING [28], specialized for the study of the interaction of small molecules that interfere with the life cycle of SARS-CoV-2 in humans, it was possible to identify the presence of possible direct interactions between hydroxytyrosol and α-cyclodextrin with the viral protein Spike and with the human proteins TMPRSS2 and ACE2 (Figures 3 and 4).
Molecular docking experiments with Autodock Vinα-based YAS ARA software [29] were performed to confirm the possibility of interaction between α-cyclodextrin and hydroxytyrosol with the spike protein and ACE2. In vitro experiments on VeroE6 animal cell lines were also performed to confirm the virostatic properties of the alphα-cyclodextrin and hydroxytyrosol compounds [30],
A preferred formulation of the invention therefore provides for the application of the composition in the prevention of SARS-CoV-2 infection. Prevention takes place in a specific and effective way. At the same time, the combination can obviously have other virucidal or therapeutic effects, such as those already known for hydroxytyrosol. In particular, the above mentioned bacteriostatic effects can be exploited. A further preferred embodiment of the invention, involves the simultaneous application of the composition in combating halitosis due to prolonged mask use. Hypothetical is the application of the composition also only for contrasting halitosis in subjects who wear a mask for prolonged times.
Advantageously, the components of the composition are present in effective quantities, that is, effective in the prevention of SARS-CoV-2 infection, as shown by the observational and interventional studies conducted.
Preferably, the composition is present in the form of an aqueous solution in which hydroxytyrosol is present in a concentration of about 3.80-11.40% (m/m) and α-cyclodextrin is present in a concentration of about 0.20-0.60% (m/m). The specific solution mentioned above
has a density of 1.1 g/ml. Also lower concentrations of hydroxytyrosol (from 1.00 to 11.40 % (m/m)) in the combination have been shown to be effective in contrasting halitosis. In this case, the density varies from 1.0 to 1.1 g/ml. Other solvents or excipients are conceivable, as it is conceivable to add further components usual in the sector, such as flavorings. The composition according to the invention, thanks to the hypothesized operating mechanism, can have oral application in the form of a spray. Alternatively, the application can be nasally. Nasal or oral applications as a spray or also in liquid form are feasible, in particular as a mouthwash, which is particularly suitable for combating halitosis.
Thus, oral or nasal applications by spray or in liquid formulation are conceivable, for example as a food supplement, medical device, cosmetic mouthwash, traditional medicinal product of plant origin (botanical), food for special medicinal purposes.
In a very advantageous variant of the invention, oral application or oral administration by means of a spray or as a mouthwash, involves applying the composition to the oropharyngeal mucosa. In another very advantageous embodiment of the invention, the oral application via spray, or alternatively as a mouthwash, or the nasal administration foresees an application of the composition on the nasal or oropharyngeal mucosa. This application and the following action of the composition as described above presents an opportunity to strengthen the defenses through the non-specific but effective reduction against SARS-CoV-2 of the process of lipid raft mediated endocytosis and consequently of prevention [2], also taking advantage of the fact that the virus probably stops and replicates exponentially for two days on the mucous membranes before its diffusion in the lower airways [31], thus interfering with endocytosis, the biological cycle of the virus is limited, made by exocytosis, endocytosis and multiplication. Furthermore, as already explained above, in its formulation as a mouthwash, the composition has a bacteriostatic effect that reduces the growth in the oral cavity of bacteria responsible for halitosis from prolonged use of the mask [27],
In an Advanced Statistics for Drug and Diet Exploration, Repurposing, and Approval (ASDERA) study [32] there is a different approach of using α-cyclodextrin alone to inhibit the entry of SARS-CoV-2, which is based on oral administration and intestinal absorption of the active ingredient. Advantageously, application on the oropharyngeal mucosa is an application as a spray that performs its action topically. Alternatively, the application on the oropharyngeal mucosa is an
application as a mouthwash that performs its action topically. Alternatively, the application is done on the nasal mucosa, in particular as a spray.
According to a variant of the invention, the application involves repeated applications, even without time limitations, preferably twice a day, preferably after careful oral hygiene, each for a total of 0.5 ml of the aqueous solution as specified above. Preferably, each 0.5 ml dose is applied with four sprays from a spray dispensing device, each spray delivering approximately 0.125 mL of solution.
The inventors therefore propose for the first time the use of the combination of hydroxytyrosol and α-cyclodextrin to strengthen non-specific defenses through the reduction of the endocytosis process and consequent reduction of the risk of SARS-CoV-2 infection based on the principle that α-cyclodextrin inhibits lipid raft mediated endocytosis and hydroxytyrosol has a destabilizing action on the plasma membrane. Bioinformatics studies show how both hydroxytyrosol and α-cyclodextrin interact with the proteins necessary for viral endocytosis.
A second aspect of the invention concerns a dispensing device which comprises (i) a container containing the composition according to the invention;
(ii) a spray head for dispensing the composition.
The market offers various systems and medical devices useful for this purpose, such as classic aerosol dispensers or spray cans. In particular for the aqueous solution described above, the spray head is advantageously adapted to deliver doses after activation, the multiple of which, preferably four, corresponds to 0.5 ml of said aqueous solution. Alternatively, the multiple corresponds to 1 mL of said aqueous solution. It thus allows the application of correct amounts of the active ingredients. Alternatively, eight spray doses are foreseen which correspond to 0.5 or 1 mL of solution.
The device according to the invention can also comprise the composition according to the invention in the form of a mouthwash.
A further aspect of the invention concerns a method for the treatment or the prevention of SARS-CoV-2 infection which involves the application of the composition according to the invention in particular on the oropharyngeal mucosa, or in alternative on the nasal mucosa. It is therefore the use of the composition according to the invention for the prevention of SARS- CoV -2 infection.
It is therefore the use of the composition according to the invention for the prevention of SARS- CoV-2 infection. Preferably, the application takes place in concentrations (dosages) and according to the administration plan illustrated above.
A final aspect of the invention relates to a process for the production of a composition referred to in which α-cyclodextrin and hydroxytyrosol and/or their nutraceutical and/or pharmaceutically acceptable derivatives are mixed. Preferably, the two components are dissolved in water, in particular in the amounts indicated above.
The features described for one aspect of the invention can be transferred mutatis mutandis to the other aspects of the invention. The variants of the invention described above achieve the intended scopes of the invention. The composition according to the invention is effective in preventing SARS-CoV-2 infection, has no side effects, shows no cytotoxic effects and contains nutraceutical components.
The aforementioned scopes and advantages will be further highlighted during the description of a preferred embodiment example of the invention given by way of non-limiting example. Variants of the invention are the subject of dependent claims. The description of the preferred embodiment example of the composition according to the invention and of the method of application is given by way of non-limiting example with reference to the attached drawings.
In practice, the materials used, as well as the dimensions, numbers and shapes, provided they are compatible with the specific use if not otherwise specified, may be any according to requirements. Furthermore, all the details can be replaced by other technically equivalent elements.
DESCRIPTION OF A PREFERRED EMBODIMENT EXAMPLE
Brief description of the figures Fig. 1 shows the results of a cytotoxicity test of a spray containing α-cyclodextrin and hydroxytyrosol on the human cell line Caco-2.
Fig. 2 shows the results of a cytotoxicity test of a spray containing α-cyclodextrin and hydroxytyrosol on the human cell line HepG2.
Fig. 3 shows the potential binding sites of hydroxytyrosol with the proteins ACE2, TMPRSS2 and Spike.
Fig. 4 shows the potential binding sites of α-ciclodestrina with the proteins ACE2, TMPRSS2 and Spike.
Fig. 5 shows growth inhibition, ranging from 20 to 80%, in cultures of Candida albicans (A), Staphylococcus aureus (B) and a mix of bacteria (Streptococcus sp., Staphylicoccus sp. and Neisseria sp.) from throat swab (C), grown in standard culture medium (below) and in standard culture medium with the addition of mouthwash according to the invention (above).
Fig. 6 shows the reduction of DNA amplification by PCR of bacterial (A) and fungal (B) DNA after using the mouthwash (samples 7, 8 and 9) in individuals who have worn the mask continuously for 8 hours, while it is highlighted a greater presence of bacteria and fungi after using the mask for 8 hours without using mouthwash.
In vitro and in vivo experimentation for the safety and efficacy profiles for the prevention of SARS-CoV-2 infection
In an embodiment example of the invention, an aqueous solution of α-cyclodextrin and hydroxytyrosol is produced in which hydroxytyrosol is present in a concentration of 3.80 - 11,40 % (m/m), whereas α-cyclodextrin has a concentration of 0.20-0.60% (m/m). The solution is transferred into a spray dispensing device and is thus usable as a spray. In vitro, the spray of the invention is not cytotoxic as observed in two human cell lines, Caco2 and HepG2 (Figures 1 and 2) at increasing concentrations (MEM = Modified Eagle’s Medium; DMSO = dimethyl sulfoxide).
The composition has antioxidant properties as showed in a ORAC assay (Oxygen Radical Absorbance Capacity), that demonstrate an antioxidant capacity of 1,247.43 ± 4.05 pmol TE/ml (micromoles of Trolox® (TE) per milliliter of the sample). Interestingly, the antioxidant properties of the human milk of mothers fed with a Mediterranean diet has an antioxidant power of 584.16 ± 29.51 pmol TE/ml.
The spray was tested on 87 volunteers negative for COVID-19 and with different clinical characteristics (table 1) in a observational study without controls. None of these individuals after using the spray for a week has shown any side effects or interactions with drugs taken for other diseases.
The volunteers took two doses per day, each dose corresponds to four spray doses for a total of 0.5 ml of solution (3.80 % (m/m) of hydroxytyrosol and 0.20% (m/m) of α-cyclodextrin.
Since the participants were all residents of Lombardy and given that 1% of the population was infected at the peak period [33], at least one affected patient was expected among the participants, but at the end of the study they were all negative for the virus.
* Continuous exposure means health workers in continuous contact with COVID-19 patients or cohabiting with sick subjects. By occasional, we mean any contact with a casual and not protracted positive subject as it can be in public transport or at a restaurant.
The results shown in Table 1 are a first clue to the effectiveness of the spray in the prevention of COVID-19. The use of the spray by peopl e with a greater risk of contracting the infection, such as healthcare workers or family members of affected patients, gives a strong indication of
the reduction of the risk of contracting the infection. The percentage of subjects who can acquire the infection after contact at risk is not certain, but it is estimated that it can range from a minimum of 30% of contacts up to 80%. Wang et al. demonstrated that 47 (30%) of 155 close contacts tested positive with SARS-CoV-2, indicating that the secondary transmission rate among family contacts of SARS-CoV-2 patients was 30% [34], Other recently published studies highlight how it is possible to find, in the context of different family clusters, much higher percentages, which reach a maximum of 80% of contacts [35], A difference of 20% can therefore be considered between non-prophylaxed subjects (in which we assume a 30% acquisition of infection) and those who have been prophylaxed (in which we assume a 10% acquisition of infection).
The invention achieved the aim of proposing a composition with nutraceutical active ingredients that are effective in preventing SARS-CoV-2 infection and that do not have side effects or signs of cytotoxicity. The proposed oral administration allows in particular the local (topical) action of the two components in the oropharyngeal mucosa, made possible by the particular combination of α-cyclodextrin and hydroxytyrosol.
In the executive phase, further modifications or executive variants not described may be made to the composition and other related aspects, subject of the invention. Should such modifications or variants fall within the scope of the following claims, they must all be considered protected by this patent. In collaboration with the "Near East” University of Nicosia (Cyprus), the spray was tested on 90 SARS-CoV-2 negative volunteers at the start of the study to further evaluate its safety and effectiveness in preventing infection. After 30 days of using the spray, no volunteers was tested positive for the swab and/or serological test (Table 2).
* Continuous exposure means health workers in continuous contact with COVID-19 patients or cohabiting with sick subjects. By occasional, we mean any contact with a casual and not protracted positive subject as it can be in public transport or at a restaurant.
Finally, the spray was tested in a small cohort of 6 swap positive patients after real time PCR assay for SARS-CoV-2. The biology of the virus reminds us that swap positivity does not always correspond to the clinical manifestation of the disease. Therefore, the use of the spray in the absence of a clinical diagnosis of the disease can still be useful. Of these 6 patients, 2 used the spray. It is interesting to note that the two treated patients became negative after 3 days, while the 4 untreated patients became negative after 6 days (Table 5), this data further supports the role of the spray in strengthening the non-specific defenses against viruses that attack the organism through lipid raft mediated endocytosis, and in particular against the SARS- CoV-2 virus.
Fig. 3 illustrates the potential binding sites of hydroxytyrosol with the proteins ACE2, TMPRSS2 and Spike, while fig. 4 illustrates the potential binding sites of α-cyclodextrin with ACE2, TMPRSS2 and Spike proteins.
As shown above, with the bioinformatic tool D3DOCKING [28], specialized for the study of the interactions of small molecules that interfere with the biological cycle of SARS-CoV-2 in humans, it was possible to find the presence of possible direct interactions between
hydroxytyrosol and α-cyclodextrin with the viral protein Spike and with the human proteins TMPRSS2 and ACE2. Table 3 shows the details relevant for the figure 3, table 4 refers to fig.4.
*PDB = protein data bank
Molecular docking experiments were performed using Autodock Vinα-based YASARA software [29] to confirm the possibility of interaction between α-cyclodextrin and hydroxytyrosol with the spike protein and ACE2. The results showed that α-cyclodextrin can bind to both the viral spike protein and the host receptor protein ACE2 with a significantly higher binding affinity than hydroxytyrosol for the same proteins. The binding energies of α- cyclodextrin and hydroxytyrosol to ACE2 were 7.91 kcal/mol and 6.10 kcal/mol, respectively, while the corresponding binding energies to the spike protein were 6.40 kcal/mol and 6.41 kcal/mol, respectively. In conclusion, both compounds could inhibit the two targets by virtue of their significant binding affinities. These compounds can also form physical bonds with each other, and the resulting complex is predicted to bind efficiently to both proteins. Compared to its components, the binding energy of the complex is significantly higher for the ACE2 receptor and similar to the separate compounds for the spike protein [36], Finally, in vitro experiments were performed on animal cell lines, VeroE6. These experiments showed that at 0.8 pM a solution containing α-cyclodextrin and hydroxytyrosol is not cytotoxic and is able to inhibit viral replication (Table 6) [30],
Further clinical studies The clinical data of the 225 subjects (heterogeneous in age, sex, comorbidities and drug use, with no significant differences from the general population) who used the spray for 30 days and those who did not use it are included in Tables 7 and 8. All participants were followed up for 30 days until the last spray administration. Although all the participants were at increased risk of becoming infected with SARS-CoV-2 due to their occupation, none of the users of the spray- showed any side effects and none of them acquired the infection even though while
administering the spray they have certainly been in contact with at least 7 of their colleagues, who contracted the virus by attending the same work environment as 12 users of the spray [30], The clinical data for the subjects that used the spray are listed in table 7.
The clinical data of subjects that did not use the spray are listed in the following table 8.
Table 8
In vitro and in vivo testing of the application of hydroxytyrosol and α-cyclodextrin in the form of mouthwash to counteract halitosis due to prolonged use of facial mask
The possible inhibition of the growth of microorganisms by a mouthwash containing the composition according to the invention was evaluated: hydroxytyrosol and α-cyclodextrin. The following microorganisms were isolated from throat swabs collected by sterile swabs and cultured:
1) Candida albicans (isolated from a lingual swab)
2) Staphylococcus aureus (isolated from pus culture)
3) Mix of bacteria from throat swab containing Streptococcus sp., Staphylicoccus sp. and Neisseria sp.
The microorganisms were inoculated into a standard liquid medium called Brain Heart Infusion (BHI) agar (Liofilchem).
Media with the microorganisms were incubated at 37 °C for 4 hours in order to reach the logarithmic growth phase. Four tubes containing 2ml of BHI medium and 4 tubes containing 1ml of BHI and 1ml of mouthwash were prepared. In each tube 100 μl of liquid medium from logarithmic cultures were inoculated. In order to obtain 1) a tube with 2ml of BHI medium inoculated with 100 μl of medium containing Candida albicans and a tube with 1ml of BHI medium + 1 ml of mouthwash inoculated with 100 μl of medium containing Candida albicans,' 2) a tube with 2ml of BHI medium inoculated with 100 μl of medium containing Staphylococcus aureus and a tube with 1ml of BHI medium + 1 ml of mouthwash inoculated with 100 μl of medium containing Staphylococcus aureus, 3) a tube with 2ml of BHI medium inoculated with 100 μl of medium containing a mix of bacteria from throat swab and a tube with 1ml of BHI medium + 1 ml of mouthwash inoculated with 100 μl of medium containing a mix of bacteria from throat swab. After an overnight incubation of all cultures at 37 °C, 1 pl was inoculated on solid media in Petri dishes divided into two parts: one with BHI medium and one with BHI medium and mouthwash. Sabouraud Dextrose Agar (Biolife) was used for C albicans, while Columbia Blood Agar (Biolife) for the other cultures. After incubation at 37 ° C overnight, a growth difference highlighted in figure 5 was confirmed, figure 5 illustrates the inhibition of the growth that oscillates between 20 and 80 %, in the cultures of Candida albicans (A), Staphylococcus aureus (B) and a mix of bacteria (Streptococcus sp., Staphylicoccus sp. and Neisseria sp.) from
throat swap (C), cultivated in standard culture medium (below) and in standard culture medium withy adding a mouthwash according to the invention (above).
From the experimental data obtained, an evident inhibition of growth was observed, oscillating between 20 and 80%, in particular in the culture from throat swab. In fact, the mixed flora of Streptococcus sp., Staphylococcus sp. and Neisseria sp. is the most similar to the real microbial flora of the oral cavity [27],
In a further experiment to evaluate the effect of the mouthwash, DNA was extracted from saliva in three volunteers: without using the mask, after using the mask for 8 hours, after they had used the mask for 8 hours and then used the mouthwash. Then the extracted DNA was amplified with universal primers (for example Universal 16S rRNA bacterial primers 27F and Universal
Panfungal ITS) for the amplification of bacterial and fungal DNA as described in the references [37,38], to evaluate possible differences in microbial growth with or without the use of the facial mask and with or without the use of the mouthwash. It has been shown that there is an increase in bacterial and fungal growth when wearing the mask for 8 hours, while when the volunteers wore the mask for 8 hours and then used the hydroxytyrosol and α-cyclodextrin- based mouthwash, a reduction in the presence of bacteria and fungi was found, even compared to those who did not use the mask for 8 hours (figure 6) [27],
Figure 6 show s ladders of DNA, wherein A (ladder 1 kb) refers to the primer Universal 16S rRNA bacterial primers 27F with a fragment length of 1440 bp and B (ladder 100 bp) to the primer Universal Panfungal ITS with a fragment length of 500 bp. From the left to the right, results without mask, with a use of the mask for 8 hours and with a use of the mask together with an application of the mouthwash according to the invention can be noted.
A 10 days study has been performed. In the first 5 days, 12 volunteers did not use the mouthwash, while in the remaining 5 days the same volunteers used the mouthwash. As a basic assumption it was considered that all volunteers use toothbrushes and toothpaste after each meal and wear the mask for 8 hours a day. After that, these volunteers were given a questionnaire to assess whether they had experienced halitosis at the beginning of the study and if they perceived improvements after the use of the mouthwash at the end of the study. At the end of the study, a strong tendency was found towards a reduction of subjects with halitosis from 9 to 2, with gingival inflammation from 6 to 2 and of the oral cavity from 8 to 2, and dryness of the oral
cavity from 5 to : [27] (Table 9 lists the answers to the questionnaire concerning the use of the mouthwash.).
Bibliographic references :
[1] L. Liu, Q. Wei, K. Nishiura, J. Peng, H. Wang, C. Midkiff, X. Alvarez, C. Qin, A. Lackner, Z. Chen; Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques. Mucosal Immunol. 2016; 9 : 1089- 1101. (doi : 10.1038/mi .2015.127).
[2] A. A. Caruso, A. Del Prete, A. I. Lazzarino, R. Capaldi, L. Grumetto; Might hydrogen peroxide reduce the hospitalization rate and complications of SARS-CoV-2 infection? Infect. Control Hosp. Epidemiol. 2020: 1-2. (doi: 10.1017/ice.2020.170).
[3] C.-C. Lai, T.-P. Shih, W.-C. Ko, H.-J. Tang, P.-R. Hsueh; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents 2020,55(3): 105924. (doi : 10.1016/j . ij antimi cag.2020.105924) .
[4] M. Marsh, A. Helenius; Virus entry: Open sesame. Cell 2006; 124:729-740. (doi : 10.1016/j. cell.2006.02.007).
[5] J. Glende, Chr. Schwegmann-Wessels, M. Al-Falah, S. Pfefferle, X. Qu, H. Deng, Chr. Drosten, H. Y. Naim, G. Herd er; Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavir us with the cellular receptor angiotensinconverting enzyme 2. Virology 381 (2008) 215-221 (doi.org/10.1016/j.virol.2008.08.026).
[6] K. Simons, E. Ikonen; Functional rafts in cell membranes . Nature 387 (1997) 569 - 572 (doi: 10.1038/42408).
[7] R. Nomura, A. Kiyota, E. Suzaki, K. Kataoka, Y. Ohe, K. Miyamoto, T. Senda, T. Fujimoto; Human. Coronavirus 229E Binds to CD 13 in Rafis and Enters the Cell through Caveolae. J. Virol. 78 (2004) 8701 - 8708 (doi: 10.1128/JVI.78.16.8701-8708.2004)
[8]E. B. Thorp, T. M. Gallagher; Requirements for CEACAMs and Cholesterol during Murine Coronavirus Cell Entry. J. Virol. 78 (2004) 2682 - 2692 (doi: 10.1128/JVI.78.6.2682- 2692.2004).
[9] Y. Lu, D. X. Liu, J. P. Tara, Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem. Biophys. Res. Commun. (2008) 369(2):344 - 349
(doi: 10.1016/j .bbrc.2008.02.023).
[10] H. Guo, M. Huang, Q. Yuan, Y. Wei, Y. Gao, L. Mao, L. Gu, Y. W. Tan, Y. Zhong, D. Liu, Sh. Sun; The Important Role of Lipid Raft-Mediated A ttachment in the Infection of Cultured Cells by Coronavirus Infectious Bronchitis Virus Beaudette Strain. PLoS ONE (2017) 12(1): e0170123 (doi: 10. 1371/joumal. pone.0170123).
[11] R. Zidovetzki, I. Levitan; Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim. Biophys. Acta (2007) 1768(6): 1311 - 1324 (doi: 10.1016/j. bbamem.2007.03.026).
[12] M. Baglivo, M. Baronio, G. Natalini, T. Beccari, P. Chiurazzi, E. Fulcheri, P. Petralia, S. Michelini, G. Fiorentini, G. A. Miggiano, A. Morresi, G. Tonini, M. Bertelli; Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? Acta Biomed. 2020; Vol. 91 (1): 161-164
[13] G.-M. Li, Y.-G. Li, M. Yaraate, Sh.-M. Li, K. Ikuta; Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronα-virus life cycle. Microbes Infect. (2007) 9:96-102 (doi: I0.10I6/j.micinf.2006.10.015).
[14] G. Li, J. Kim, Zh. Huang J. R. St. Clair, D. A. Brown, E. London; Efficient replacement of plasma membrane outer leafle t phospholipids and sphingolipids in cells with exogenous lipids.
PNAS 113 (49) (2016) 14025 - 14030 (doi.org/10.1073/pnas.1610705113).
[15] K. M. Wittkowski; A Novel Formulation of α-Cyclodextrin for Use as a Natural Anti- Aging 'Intermittent Fasting Mimetic ’ . (2019)
(https://app.box. com/s/j 3of6yxbd7dn8fp4guce003 b7awokai 1 ).
[16] K. M. Wittkowski, Chr. Dadurian, M. P. Seybold, H. S. Kim, A. Hoshino, D. Lyden; Complex polymorphisms in endocytosis genes suggest alphα-cyclodextrin as a treatment for breast cancer. PLoS ONE (2018) 13(7): e0199012 (doi.org/10.1371/jounial. pone.0199012).
[17] S. T. Jones, V. Cagno, M. Janecek, D. Ortiz, N. Gasilova, J. Piret, M. Gasbarri, D. A. Constant, Y. Han, L. Vukovic, P. Kral, L. Kaiser, S. Huang, S. Constant, K. Kirkegaard, G. Boivin, F. Stellacci, C. Tapparel; Modified cyclodextrins as broad-spectrum antivirals. Sei. Adv. 2020; 6(5):eaax9318 (doi: 10.1 126/sciadv.aax9318).
[18] K. Yamada, H. Ogawa, A. Hara, Y. Yoshida, Y. Yonezawa, K. Karibe, V. Bui Nghia, H. Yoshimura, Y. Yamamoto, M. Yamada, K. Nakamura, K. Imai; Mechanism of the antiviral effect of hydroxytyrosol on influenza virus appears to involve morphological change of the virus. Antiviral Res. 2009, 83(l):35-44 (doi. org/10.1016/j. antiviral.2009.03.002).
[19] S.T. Yang, V. Kiessling, J. A. Simmons, J.M. White, L.K. Tamm; HIV gp41 -mediated membrane fusion occurs at edges of cholesterol-rich lipid domains. Nat. Chem. Biol. (2015); 11 (6):424-31 (doi : 10.1038/nchembio.1800). [20] S. Lee-Huang, P. L. Huang, D. Zhang, J. W. Lee, J. Bao, Y. Sun, Y.-T. Chang, J. Zhang,
P. L. Huang; Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxy tyrosol: Part 1. fusion [corrected] inhibition. Biochem. Biophys. Res. Commun. (2007) 354(4):872-8 (doi: 10.1016/j .bbrc.2007.01 .071).
[21] S. Lee-Huang, Ph. L. Huang, D. Zhang, J. W. Lee, J. Bao, Y. Sun, Y.-T. Chang, J. Zhang, P. L. Huang; Discovery of small-molecule HIV- 1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: part II. integrase inhibition. Biochem. Biophys. Res. Commun. (2007) 354(4):879-84 (dot: 10.1016/j bbrc.2007.01 .058).
[22] M. J. Ramirez-Exposito, J. M. Martinez-Martos. Anti-Inflammatory and Antitumor Effects of Hydroxytyrosol but Not Oleuropein on Experimental Glioma In Vivo. A Putative Role for the Renin-Angiotensin System . Biomedicines 2018; 6( 1): 11 (doi:10.3390/biomedicines6010011).
[23] H. Jemai, I. Fki, M. Bouaziz, Z. Bouallagui, A. El Feki, H. Isoda, S. Sayadi, Lipid- Lowering and Antioxidant Effects of Hydroxytyrosol and Its Triacetylated Derivative Recovered from Olive Tree Leaves in Cholesterol-Fed Rats. J. Agric. Food Chem. (2008); 56(8):2630-2636 (doi: 10.1021/jf072589s). [24] S. Lopez, B. Bermudez, S. Monserrat-de la Paz, S. Jaramillo, L. M. Varela, A. Ortegα-
Gomez, R. Abia, F. J. G. Muri ana; Membrane composition and dynamics: A target of bioactive
virgin olive oil constituents. Biochim. Biophys. Acta 1838 (2014) 1638 - 1656 (doi : 10.1016/j .bbamem.2014.01.007).
[25] J. Thielmann, S. Kohnen, C. Hauser; Antimicrobial activity of Olea europaea Linne extracts and their applicability as natural food preservative agents. Int. J. Food Microbiol. 2017;251 :48-66. (doi:10.1016/j.ijfoodmicro.2017.03.019).
[26] J. Wei, S. Wang, D. Pei, L. Qu, Y. Li, J. Chen, D. Di, K. Gao; Antibacterial activity of hydroxytyrosol acetate from olive leaves (Olea europaea L.). Nat, Prod. Res. 2018;32(16): 1967-1970. (doi: 10.1080/14786419.2017.1356830).
[27] Naureen Z, Capodicasa N, Anpilogov K, Coatto M, Paolacci S, ManaraE, Dautaj A, Dhuli K, Camilleri G, Bertelli M. Prevention of the proliferation of oral pathogens due to prolonged mask use based on alphα-cyclodextrin and hydroxytyrosol mouthwash. Submitted to the European Reviews for Medical and Pharmacological Sciences
[28] https://www.d3pharma.com/D3Targets-2019-nCoV/D3Docking/index.php
[29] O. Trott O, A.J. Olson; AutoDock VINA: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 2010;31 :455-461. (doi: 10.1002/jcc.21334).
[30] Paolacci S, Ergoren MC, De Forni D, Manara E, Poddesu B, Cugia G, Dhuli K, Camilleri G, Tuncel G, Suer HK, Sultanoglu N, Sayan M, Dundar M, Gunsel IS, Coatto M, Dautaj A, Sanlidag T, Connelly ST, Tartaglia GM, Bertelli M. In vitro and clinical studies on the efficacy of alphα-cyclodextrin and hydroxytyrosol against SARS-CoV-2 infection. Submitted to European Review for Medical and Pharmacological Sciences
[31 ] L. Liu, Q. Wei, K. Nishiura, J. Peng, H. Wang, C. Midkiff, X. Alvarez, C. Qin, A. Lackner, Z. Chen; Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques. Mucosal Immunol. 2016; 9: 1089-1101 (doi: 10.1038/mi.2015.127).
[32] http :/7www. asdera. com/sars-nutriti on.htnil
[33] https://lab24.ilsole24ore.com/coronavirus/.
[34] Zh. Wang, W. Ma, X. Zheng, G. Wu, R. Zhang; Household transmission of SARS-CoV-2.
J. Infec. 81 (2020) 179-182 (doi: 10.1016/j .jinf.2020.03.040). [35] K. Danis, O. Epaulard, Th. Benet, A. Gaymard, S. Campoy, E. Botelho-Nevers, M.
Bouscambert-Duchamp, G. Spaccaferri, F. Ader, A. Mailles, , Boudalaa, V. Tolsma, J. Berra,
S. Vaux, E. Forestier, C. Landelle, E. Fougere, A. Thabuis, Ph. Berthelot, R. Veil, D. Levy- Bruhl, Chr. Chidiac, B. Lina, B. Coignard, Chr. Saura; Chisler of Coronavirus Disease 2019 (COVID-19) in the French Alps, February 2020. Clinical Infectious Diseases (2020); 71 (15): 825-832 (doi: 10.1093/cid/ciaa424). [36] Paolacci S, Kiani AK, Shree P, Tripathi D, Tripathi YB, Tripathi P, Tartaglia GM,
Farronato M, Farronato G, Connelly ST, Beccari T, Ceccarini MR, Coatto M, Ergoren MC, Sanlidag T, Dautaj A, Bertelli M. Scoping review on the role and interactions of hydroxytyrosol and alphα-cyclodextrin in lipid-raft-mediated endocytosis of S ARS-CoV-2 and bioinformatic molecular docking studies. Submitted to European Review for Medical and Pharmacological Sciences
[37] Miller CS, Handley KM, Wrighton KC, Frischkom KR, Thomas BC, Banfield JF. Shortread assembly of full-length 16S amplicons reveals bacterial diversity in subsurface sediments. PLoS One 2013;8(2):e56018. doi: 10.1371/joumal. pone.0056018
[38] Meason-Smith C, Edwards EE, Older CE, Branco M, Bryan LK, Lawhon SD, Suchodolski JS, Gomez G, Mansell J, Hoffmann AR. Panfungal polymerase chain reaction for identification of fungal pathogens in formalin-fixed animal tissues. Vet Pathol 2017;54(4):640-648. doi: 10. 1177/0300985817698207
[39] Thayer RE. The biopsychology of mood and arousal. New York: Oxford University Press, 1989 [40] Orszaghova Z, Waczulikova I, Burki C, Rohdewald P, Durackova Z. An effect of oak- wood extract (Robuvit®) on energy state of healthy adults - A pilot study. Phyt other Res 2015; 29(8): 1219-1224
Claims
1) Composition comprising:
(a) α-cyclodextrin, and (b) hydroxytyrosol and/or their nutraceutically acceptable derivatives, such as salts or esters.
2) Composition according to claim 1 for application as a food supplement or with a medical device.
3) Composition according to claim 1 for application as medical device, cosmetic mouthwash, traditional medicinal product of plant origin (botanical) or food for special medical purposes, in particular as a mouthwash. 4) Composition according to the claim 1, 2 or 3 for use in the prevention of the SARS-CoV-2 infection.
5) Composition according to claim 4 for the contemporaneous reduction of halitosis for prolonged use of a mask.
6) Composition according to claim 4 or 5, characterized in that the two components are present in an effective amount.
7) Composition according to claim 6, characterized in that said composition is present in the form of an aqueous solution wherein hydroxytyrosol is present in a concentration of about 3.80
- 11.40 % (m/m) and said α-cyclodextrin is present in a concentration of about 0.20 - 0.60 % (m/m).
8) Composition according to anyone of the previous claims, characterized in that said use takes place by oral administration.
9) Composition according to anyone of the previous claims, characterized in that said use takes place by nasal administration.
10) Composition according to claim 8, characterized in that sad administration is an administration on the oropharyngeal mucosa.
11) Composition according to claim 9, characterized in that sad administration is an administration on the nasal mucosa. 12) Composition according to claim 10 or 11, characterized in that said administration on the oropharyngeal or nasal mucosa is an application as liquid or spray.
13) Composition according to claims 7 and 10, characterized in that said administration is an application as a spray and foresees repeated administrations, preferably two per day, each of about 0.5 ml of said aqueous solution.
14) Composition according to claims 7 and 12, characterized in that said administration is an application as a mouthwash and foresees repeated administrations, preferably two per day, each of about 5 ml of said aqueous solution.
15) Mouthwash comprising the composition according to anyone of the claims from 1 to 8, 10, 12 or 14.
16) Dispensing device comprising (i) a container containing the composition according to anyone of the previous claims;
(ii) a spray head for dispensing said composition.
17) Dispensing device according to claim 16, characterized in that the spray head is adapted to dispense doses after activation, the multiple of which, preferably four or eight, corresponds to about 0.5 or 1 ml of said aqueous solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/031,551 US20230372264A1 (en) | 2020-10-13 | 2021-04-07 | Composition for the prevention of infection by sars-cov-2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102020000024118A IT202000024118A1 (en) | 2020-10-13 | 2020-10-13 | COMPOSITION FOR THE PREVENTION OF SARS-COV-2 INFECTION |
IT102020000024118 | 2020-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022079498A1 true WO2022079498A1 (en) | 2022-04-21 |
Family
ID=74068454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2021/052900 WO2022079498A1 (en) | 2020-10-13 | 2021-04-07 | Composition for the prevention of infection by sars-cov-2 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230372264A1 (en) |
IT (1) | IT202000024118A1 (en) |
WO (1) | WO2022079498A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050274672A1 (en) * | 2000-02-02 | 2005-12-15 | Hosheng Tu | Extracorporeal pathogen reduction system |
WO2006117029A1 (en) * | 2005-04-29 | 2006-11-09 | Lucas Huybrechts | Use of polylysine in combination with either green tea or olive extracts or both for use against halitosis |
JP2009195185A (en) * | 2008-02-22 | 2009-09-03 | Japan Tobacco Inc | Beverage for reducing halitosis |
JP2013129641A (en) * | 2011-12-22 | 2013-07-04 | Lion Corp | Composition for oral cavity and foul breath inhibitor |
-
2020
- 2020-10-13 IT IT102020000024118A patent/IT202000024118A1/en unknown
-
2021
- 2021-04-07 US US18/031,551 patent/US20230372264A1/en active Pending
- 2021-04-07 WO PCT/IB2021/052900 patent/WO2022079498A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050274672A1 (en) * | 2000-02-02 | 2005-12-15 | Hosheng Tu | Extracorporeal pathogen reduction system |
WO2006117029A1 (en) * | 2005-04-29 | 2006-11-09 | Lucas Huybrechts | Use of polylysine in combination with either green tea or olive extracts or both for use against halitosis |
JP2009195185A (en) * | 2008-02-22 | 2009-09-03 | Japan Tobacco Inc | Beverage for reducing halitosis |
JP2013129641A (en) * | 2011-12-22 | 2013-07-04 | Lion Corp | Composition for oral cavity and foul breath inhibitor |
Non-Patent Citations (9)
Title |
---|
ABD EL-SHAFY DINA ET AL: "Evaluation of the Antimicrobial Effect of Olive Oil Extract on Oral Microflora", AL-AZHAR DENTAL JOURNAL FOR GIRLS, vol. 5, no. 1, 1 October 2018 (2018-10-01), pages 447 - 454, XP055810626, Retrieved from the Internet <URL:https://journals.ekb.eg/article_109375_d7f1281fdb7b3c149fe809a211f789fb.pdf> DOI: 10.21608/adjg.2018.109375 * |
BERTELLI MATTEO ET AL: "Hydroxytyrosol: A natural compound with promising pharmacological activities", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM NL, vol. 309, 26 December 2019 (2019-12-26), pages 29 - 33, XP085987384, ISSN: 0168-1656, [retrieved on 20191226], DOI: 10.1016/J.JBIOTEC.2019.12.016 * |
EFMORFOPOULOU E ET AL: "Application of Cyclodextrins to the Extraction of Antioxidant Compounds from Olive Oil", CHEMISTRY OF NATURAL COMPOUNDS, SPRINGER NATURE, vol. 41, no. 1, 1 January 2005 (2005-01-01), pages 22 - 26, XP019276662, ISSN: 1573-8388 * |
ELFIKY ABDO A. ET AL: "Natural products may interfere with SARS-CoV-2 attachment to the host cell", 5 May 2020 (2020-05-05), US, pages 1 - 10, XP055807159, ISSN: 0739-1102, Retrieved from the Internet <URL:https://www.tandfonline.com/doi/pdf/10.1080/07391102.2020.1761881?needAccess=true> DOI: 10.1080/07391102.2020.1761881 * |
ERGOREN MAHMUT CERKEZ ET AL: "A pilot study on the preventative potential of alpha-cyclodextrin and hydroxytyrosol against SARS-CoV-2 transmission", ATENEO PARMENSE. ACTA BIOMEDICA, vol. 91, no. 13-S, 9 November 2020 (2020-11-09), IT, pages e2020022, XP055807029, ISSN: 0392-4203, DOI: 10.23750/abm.v91i13-S.10817 * |
ISLAM RAJIB ET AL: "A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2", 12 May 2020 (2020-05-12), US, pages 1 - 12, XP055807079, ISSN: 0739-1102, Retrieved from the Internet <URL:https://www.tandfonline.com/doi/pdf/10.1080/07391102.2020.1761883?needAccess=true> DOI: 10.1080/07391102.2020.1761883 * |
JEULIN H ET AL: "In vivo antiviral activity of ribavirin/alpha-cyclodextrin complex: Evaluation on experimental measles virus encephalitis in mice", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 357, no. 1-2, 5 June 2008 (2008-06-05), pages 148 - 153, XP022637091, ISSN: 0378-5173, [retrieved on 20080203], DOI: 10.1016/J.IJPHARM.2008.01.043 * |
NICOLAZZI CÉLINE ET AL: "Effect of the complexation with cyclodextrins on the in vitro antiviral activity of ganciclovir against Human Cytomegalovirus", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 9, no. 2, 11 June 2017 (2017-06-11), pages 275 - 282, XP085058960, ISSN: 0968-0896, DOI: 10.1016/S0968-0896(00)00247-9 * |
QUILES JOSÉ L ET AL: "Do nutrients and other bioactive molecules from foods have anything to say in the treatment against COVID-19?", ENVIRONMENTAL RESEARCH, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 191, 22 August 2020 (2020-08-22), XP086334829, ISSN: 0013-9351, [retrieved on 20200822], DOI: 10.1016/J.ENVRES.2020.110053 * |
Also Published As
Publication number | Publication date |
---|---|
US20230372264A1 (en) | 2023-11-23 |
IT202000024118A1 (en) | 2022-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200237689A1 (en) | Prevention and treatment of coronavirus and other respiratory infections using nanoemulsion compositions | |
Liu et al. | Antiviral activity and possible mechanisms of action of pentagalloylglucose (PGG) against influenza A virus | |
US11497720B2 (en) | Pharmaceutical composition comprising trans-cinnamaldehyde and its use in the treatment of infections | |
MX336318B (en) | Co-crystals of tramadol and nsaids. | |
NI201100194A (en) | DERIVATIVES OF HAVE [2, 3 - B] PYRIDINE AS INHIBITORS OF VIRAL REPLICATION | |
US10864188B2 (en) | Anti-microbial composition | |
WO2007014515A1 (en) | Use of hydroxybenzoic acid ester and analogues for the manufacture of a mendicament for the prevention and treatment of virus infection | |
BR112012030641A2 (en) | methods and compositions for oral pharmaceutical therapy | |
Zhou et al. | Application of ginsenoside Rd in periodontitis with inhibitory effects on pathogenicity, inflammation, and bone resorption | |
TW202237165A (en) | Novel compositions and methods of treatment | |
Makarov et al. | The past, present and future of RNA respiratory viruses: influenza and coronaviruses | |
KR20200072499A (en) | Novel MEK-inhibitors for the treatment of viral and bacterial infections | |
US20230372264A1 (en) | Composition for the prevention of infection by sars-cov-2 | |
US20190060220A1 (en) | Process and Method to Accelerate Cellular Regeneration, Healing and Wound Management | |
CN114007598A (en) | Novel MEK inhibitors for the treatment of viral and bacterial infections | |
WO2020208659A1 (en) | Anti-viral anti-bacterial immunoboosting composition of herbal extracts in synergistic ratios | |
EP4329743A1 (en) | Pyruvate esters for the treatment of viral diseases | |
Malani et al. | Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2 | |
MX2008015323A (en) | Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association. | |
WO2021191904A1 (en) | Methods for preventing and treating viral infection | |
JP2012229184A (en) | Antiviral drug | |
Sabracos et al. | The in vitro effective antiviral action of povidone–iodine (PVP–I) may also have therapeutic potential by its intravenous administration diluted with Ringer’s solution | |
Iraci et al. | Nanoscale technologies in the fight against COVID-19: From innovative nanomaterials to computer-aided discovery of potential antiviral plant-derived drugs | |
Chepur et al. | Respiratory RNA viruses: how to be prepared for an encounter with new pandemic virus strains | |
Siddoo-Atwal | A Proposed role for zinc supplementation in covid-19 prevention |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21722991 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21722991 Country of ref document: EP Kind code of ref document: A1 |